| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5914334 | ALLERGAN | Stable gel formulation for topical treatment of skin conditions |
Jun, 2014
(9 years ago) | |
| US6258830 | ALLERGAN | Stable gel formulation for topical treatment of skin conditions |
Jun, 2014
(9 years ago) | |
Tazorac is owned by Allergan.
Tazorac contains Tazarotene.
Tazorac has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Tazorac are:
- US5914334
- US6258830
Tazorac was authorised for market use on 13 June, 1997.
Tazorac is available in gel;topical dosage forms.
Tazorac can be used as stable gel formulation for topical treatment of skin conditions.
The generics of Tazorac are possible to be released after 07 June, 2014.
Drugs and Companies using TAZAROTENE ingredient
Market Authorisation Date: 13 June, 1997
Treatment: Stable gel formulation for topical treatment of skin conditions
Dosage: GEL;TOPICAL
More Information on Dosage
TAZORAC family patents
